In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vtesse Inc.

www.vtessepharma.com

Latest From Vtesse Inc.

Biopharma Quarterly Deal-making Statistics, Q4 2017

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.

Deals Market Intelligence

Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy

Mallinckrodt is to acquire Sucampo Pharmaceuticals for about $1.2bn. The deal brings it a short-term sales boost from Amitiza, although the constipation treatment only has a few years left before generic competition hits. Longer-term hopes lie in two Phase III products for rare diseases.

M & A Pricing Debate

Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m

Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.

Financing Business Strategies

Start-Up Quarterly Statistics: Private And Public Firms Were Prolific Fundraisers

A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Vtesse Inc.
  • Senior Management
  • Ben Machielse, Pres. & CEO
    Ravi Rao, PhD, CBO
    Michael Massaro, VP, Clinical Operations
    Kevin B Johnson, PhD, VP, Regulatory Affairs
    Jason Meyenburg, Chief Commercial Officer
    Allan Darling, PhD, VP, Tech. Operations
  • Contact Info
  • Vtesse Inc.
    Phone: (240) 801-9261
    910 Clopper Rd.
    Suite 220 S
    Gaithersburg, MD 20878
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register